Novel small-molecule therapy of Hodgkin lymphoma

References

• Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood105, 4553–4560 (2005).
   PubMed Web of Science ®Google Scholar
• Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J. Clin. Oncol.23, 6400–6408 (2005).
   PubMed Web of Science ®Google Scholar
• Schwering I, Brauninger A, Klein U et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed–Sternberg cells of Hodgkin lymphoma. Blood101, 1505–1512 (2003).
   PubMed Web of Science ®Google Scholar
• Kuppers R, Klein U, Schwering I et al. Identification of Hodgkin and Reed–Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest.111, 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia JF, Camacho FI, Morente M et al. Hodgkin and Reed–Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood101, 681–689 (2003).
   PubMed Web of Science ®Google Scholar
• Ushmorov A, Leithauser F, Sakk O et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood107, 2493–2500 (2006).
   PubMed Web of Science ®Google Scholar
• Ushmorov A, Ritz O, Hummel M et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood104, 3326–3334 (2004).
   PubMed Web of Science ®Google Scholar
• Kato N, Fujimoto H, Yoda A et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin’s lymphoma cell lines. Cell Death Differ.11(Suppl. 2), S153–S161 (2004).
   Google Scholar
• Yazbeck V, Georgakis GV, Wedgwood A, Younes A. Hodgkin’s lymphoma: molecular targets and novel treatment strategies. Future Oncol.2, 533–551 (2006).
   PubMedGoogle Scholar
• Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin’s lymphoma. Haematologica90, 1680–1692 (2005).
   PubMed Web of Science ®Google Scholar
• Wedgwood A, Younes A. Targeting lymphoma cells and their microenvironment with novel antibodies. Clin. Lymphoma Myeloma7(Suppl. 1), S33–S40 (2006).
   PubMedGoogle Scholar
• Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N. Differential signaling pathways are activated in the Epstein–Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res.64, 5251–5260 (2004).
   PubMed Web of Science ®Google Scholar
• Jucker M, Sudel K, Horn S et al. Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin’s lymphoma-derived cell line (CO). Leukemia16, 894–901 (2002).
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br. J. Haematol.132, 503–511 (2006).
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev. Anticancer Ther.6, 131–140 (2006).
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer2, 489–501 (2002).
   PubMed Web of Science ®Google Scholar
• Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol.13, 478–483 (2003).
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer6, 184–192 (2006).
   PubMed Web of Science ®Google Scholar
• Zheng B, Fiumara P, Li YV et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood102, 1019–1027 (2003).
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res.12, 2955–2960 (2006).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol.24, 4867–4874 (2006).
   PubMed Web of Science ®Google Scholar
• Zheng B, Georgakis GV, Li Y et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin. Cancer Res.10, 3207–3215 (2004).
   PubMed Web of Science ®Google Scholar
• Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood107, 1731–1732 (2006).
   PubMed Web of Science ®Google Scholar
• Spector N, Milito CB, Biasoli I, Luiz RR, Pulcheri W, Morais JC. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin’s lymphoma. Leuk. Lymphoma46, 1301–1306 (2005).
   PubMed Web of Science ®Google Scholar
• Sup SJ, Alemany CA, Pohlman B et al. Expression of Bcl-2 in classical Hodgkin’s lymphoma: an independent predictor of poor outcome. J. Clin. Oncol.23, 3773–3779 (2005).
   PubMed Web of Science ®Google Scholar
• Kim LH, Nadarajah VS, Peh SC, Poppema S. Expression of Bcl-2 family members and presence of Epstein–Barr virus in the regulation of cell growth and death in classical Hodgkin’s lymphoma. Histopathology44, 257–267 (2004).
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP et al. BCL-2 expression in Hodgkin and Reed–Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood100, 3935–3941 (2002).
   PubMed Web of Science ®Google Scholar
• Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest.115, 2648–2655 (2005).
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15–070 synergizes with bortezomib in mantle cell lymphoma by enhancing noxa-mediated activation of Bak. Blood (Epub ahead of print).
   Google Scholar
• Bebb G, Muzik H, Nguyen S, Morris D, Stewart DA. In vitro and in vivo anti lymphoma effect of GX15–070 in mantle cell lymphoma. Blood108, 4756 (2006).
   Google Scholar
• Borthakur G, O’Brien S, Ravandi-Kashani F et al. A Phase I trial of the small molecule Pan-Bcl-2 family inhibitor obatoclax mesylate (GX15–070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). Blood108, 2654 (2006).
   Google Scholar
• O’Brien S, Kipps TJ, Faderl S et al. A Phase I trial of the small molecule Pan-Bcl-2 family inhibitor GX15–070 administered intravenously (IV) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL). Blood106, 446 (2005).
   Google Scholar
• Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J. Clin. Invest.115, 2633–2639 (2005).
   PubMed Web of Science ®Google Scholar
• Neckers L, Ivy SP. Heat shock protein 90. Curr. Opin. Oncol.15, 419–424 (2003).
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol.1, 273–281 (2005).
   PubMedGoogle Scholar
• Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update. Expert Opin. Emerg. Drugs10, 137–149 (2005).
   PubMedGoogle Scholar
• Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer13(Suppl. 1), S125–S135 (2006).
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Whitesell L. Heat shock protein 90: a unique chemotherapeutic target. Semin. Oncol.33, 457–465 (2006).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Trump DL, Eiseman JL et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res.11, 3385–3391 (2005).
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature425, 407–410 (2003).
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin. Cancer Res.12, 584–590 (2006).
   PubMed Web of Science ®Google Scholar
• Monneret C. Histone deacetylase inhibitors. Eur. J. Med. Chem.40, 1–13 (2005).
   PubMed Web of Science ®Google Scholar
• Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell Biol.84, 109–121 (2005).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5, 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6, 38–51 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor OA. Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br. J. Cancer95(Suppl. 1), S7–S12 (2006).
   Google Scholar
• Doerr JR, Malone CS, Fike FM et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J. Mol. Biol.350, 631–640 (2005).
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Yazbeck VY, Li Y, Younes A. The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib. ASH Annual Meeting Abstracts108, 2260 (2006).
   Google Scholar
• Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat. Rev. Drug Discov.6, 21–22 (2007).
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O’Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res.9, 3578–3588 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol.23, 3923–3931 (2005).
   PubMed Web of Science ®Google Scholar
• Kalita A, Maroun C, Bonfils C et al. Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in Phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL). American Society of Clinical Oncology Meeting Abstracts23, 9631 (2005).
   Google Scholar
• Gelmon K, Tolcher A, Carducci M et al. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3× weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. American Society of Clinical Oncology Meeting Abstracts23, 3147 (2005).
   Google Scholar